Skip to main content
AmigoFish

Psychopharmacology and Psychiatry Updates

Psychopharmacology InstituteAudio

Format:
Podcast
New episodes:
Weekly
Typical length:
about 15 minutes
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

Covers: psychiatry, psychopharmacology, antipsychotic medications, antidepressant treatment, ocd treatment, ptsd treatment, insomnia treatment, addiction medicine

Show details and episodes come from the publisher's public feed at psychopharmacology.libsyn.com. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

This podcast gives mental health clinicians practical updates on psychopharmacology, drawing on expert interviews and presentation excerpts. Recent episodes cover adjunctive antipsychotics for major depression, buprenorphine and methadone in liver disease, catatonia treatment, prazosin for PTSD nightmares, and Z-drugs in early pregnancy.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • Which Adjunctive Antipsychotic Is Best for Major Depression?

    · 10 min

    Faculty: James Phelps, M.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.5 CMEs: Quick Take Vol. 89 - Which Adjunctive Antipsychotic Is Best for Major Depression?

    Not rated yet
  • Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents

    · 11 min

    Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: Addiction Psychopharmacology in Patients with Medical Comorbidities - Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents

    Not rated yet
  • Catatonia: Should Antipsychotics Always Be Avoided?

    · 14 min

    Faculty: Scott R. Beach, M.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 88 - Catatonia: Should Antipsychotics Always Be Avoided?

    Not rated yet
  • Prazosin for PTSD Nightmares

    · 16 min

    In this episode, we explore prazosin for PTSD-related nightmares with Dr. David Osser. He explains why prazosin stands out among alpha-1 blockers, which patients are most likely to respond, and why so many trials failed from underdosing, including how titration differs for men and women. Faculty: David Osser, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.5 CME: PTSD Psychopharmacology Algorithm - Prazosin for PTSD Nightmares: Dosing Protocols for Men and Women

    Not rated yet
  • First-Episode Psychosis in Women

    · 12 min

    Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.5 CMEs: Quick Take Vol. 87 - First-Episode Psychosis in Women: Which Antipsychotic Is the Preferred Choice?

    Not rated yet
  • Second-Generation Antipsychotics for OCD Augmentation

    · 9 min

    Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation - Second-Generation Antipsychotics for OCD Augmentation: Third-Line Agents

    Not rated yet
  • Are Z-Drugs Safe in the First Trimester of Pregnancy?

    · 17 min

    In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't increased, what the neural tube defect signal means, and how to evaluate insomnia before prescribing. Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 86 - Are Z-Drugs Safe in the First Trimester of Pregnancy?

    Not rated yet
  • Glutamatergic Augmentation in OCD

    · 16 min

    Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation - Glutamatergic Augmentation in OCD: Memantine, Riluzole, Lamotrigine and Other Agents

    Not rated yet
  • Schizophrenia: Which of Seven Antipsychotics Wins?

    · 15 min

    Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 0.75 CMEs: Quick Take Vol. 85 - Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety?

    Not rated yet
  • SSRI Dosing for OCD: Beyond FDA Guidelines

    · 9 min

    Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines - Treatment-Resistant OCD: From SSRIs to Augmentation

    Not rated yet
  • Trazodone for Insomnia and Comorbid Depression

    · 10 min

    In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia and depression, alongside its notable side effect profile. Can a decades-old antidepressant be the missing link for restorative sleep? Faculty: Paul Zarkowski, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 0.5 CMEs: Quick Take Vol. 85 - Trazodone for Insomnia and Comorbid Depression: Are the AASM Guidelines Relevant?

    Not rated yet
  • Antipsychotics, Prolactin, and Sexual Side Effects

    · 8 min

    In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know - Managing Hyperprolactinemia and Sexual Side Effects from Antipsychotic Use

    Not rated yet
  • EMERGENT-5: Cobenfy and Treatment Durability

    · 12 min

    In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CME: Quick Take Vol. 85 - Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?

    Not rated yet
  • Antipsychotics and Weight Gain

    · 14 min

    In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know - Antipsychotic-Induced Weight Gain: Prevention and Management

    Not rated yet
  • EPA vs. DHA: Fish Oil and Treatment-Resistant Depression

    · 12 min

    In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms. Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.75 CMEs: Quick Take Vol. 84 - Eicosapentaenoic Acid: Effective as Adjunctive for TRD?

    Not rated yet
  • AUD Medications and Hepatic Safety

    · 10 min

    In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder - Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status

    Not rated yet
  • GLP-1 Agonists in Serious Mental Illness: Current Evidence

    · 15 min

    In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 84 - GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?

    Not rated yet
  • Gabapentin, Topiramate & Baclofen in AUD

    · 17 min

    In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder - Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder

    Not rated yet
  • Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good

    · 17 min

    In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 84 - Benzodiazepine Tapering: Key Takeaways From New Guidelines

    Not rated yet
  • Disulfiram Unpacked: Efficacy, Risks, and Liver Safety

    · 16 min

    In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder - Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations

    Not rated yet